Insider Here, Unfortunately because of forced titration from 5mg, then 10 mg, then 15mg, there were more CV events early in Active Arm of the trial. We did not have the the in-between doses which would have helped. The data will be released toward the end of June.
Is this Dunning or Kruger? Care to explain how you know the CV events in any arm of a study blinded to the patient and investigator and sponsor? I’d like to know your secret so I can quit my day job and start trading puts and calls.
Here's the reality why we wait, The safety board would have stopped the trial early if Dulaglutide was superior concerning overall 3 point mace. That being said we can at least expect that Mounjaro is noninferior to Dulaglutide up to a 1.05 Hazard Ratio. To boil that down even further, Dulaglutide can be 5% better at MACE and Mounjaro can still achieve noninferiority. There is a little wiggle room.
Here's the reality why we wait, The safety board would have stopped the trial early if Dulaglutide was superior concerning overall 3 point mace. That being said we can at least expect that Mounjaro is noninferior to Dulaglutide up to a 1.05 Hazard Ratio. To boil that down even further, Dulaglutide can be 5% better at MACE and Mounjaro can still achieve noninferiority. There is a little wiggle room.
